Thursday 16 October, 2025
Introduction: The pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy (CRRT) is complicated. The volume of…
Read morePoster: Drug/Disease Modelling - Infection
A pharmacokinetic-pharmacodynamic model characterizing antibiotic-induced morphological changes in Pseudomonas aeruginosa from time-lapse microscopy images
Thursday 16 October, 2025
Introduction: Pseudomonas aeruginosa are Gram-negative, rod-shaped bacilli that can cause a variety of infections, ranging from relatively non-severe urinary tract infections…
Read morePlasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain
Thursday 16 October, 2025
Introduction: Vancomycin is a standard therapy for central nervous system (CNS) infections, specifically nosocomial infections, caused by Gram-positive penicillin-resistant pathogens…
Read moreModel-based assessment of early bactericidal activity of rifampicin in combination with meropenem plus amoxicillin/clavulanate among adults with rifampicin-resistant pulmonary tuberculosis
Thursday 16 October, 2025
Introduction/Objectives: Meropenem and rifampicin have been reported to have synergistic activity in vitro[1], indicating that co-administration of meropenem could decrease…
Read morePopulation pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites
Thursday 16 October, 2025
Introduction: Diarylquinolines (DARQs) have become an essential part of regimens against Mycobacterium tuberculosis (TB)1. TBAJ587 is a next-generation DARQ being…
Read moreStandards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Thursday 16 October, 2025
Introduction/Objectives: One of the milestones in tuberculosis (TB) drug development is a phase 2a trial, also known as an early…
Read moreTowards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth.
Thursday 16 October, 2025
Introduction and objectives: Antimicrobial resistance is on the rise globally. Increased levels of resistance have been reported across bacterial strains…
Read morePopulation pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg
Thursday 16 October, 2025
Introduction: Dolutegravir (DTG) and lamivudine (3TC) fixed dose combination (FDC, 50/300 mg) is marketed as DOVATO which provides a novel,…
Read morePopulation pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis
Thursday 16 October, 2025
Objectives: The current WHO guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) recommend that linezolid, an oxazolidinone, is a preferred drug…
Read morePower to characterize exposure-response relations in phase IIa tuberculosis (TB) trials using bacterial load modeling
Thursday 16 October, 2025
Background: A milestone in the development of novel anti-TB drugs is demonstrating the early bactericidal activity (EBA) in a phase…
Read more